Saint Louis Rheumatology

It is with mixed emotions that we announce Physician Assistant Beatrice Bernhart, PA-C will be leaving the practice, effective April 9, 2026. We appreciate Beatrice's dedication to patient care and wish her the best in her future endeavors. Please rest assured that our providers will continue to offer you the same high level of care. Your medical records will remain on file, and the team is ready to support a seamless transition. If you need help selecting another provider within the practice, our staff will be happy to assist.
Contact the practice at 314-645-4434 with any questions or to discuss future care needs. The practice appreciates your understanding and continued trust.

Now that the federal government has reopened, Congress must act to finalize the Fiscal Year 2026 budget and increase funding for programs.

Your members of Congress need to hear from you! Without a full-year budget, all lupus programs may be cut or eliminated, putting continued advancements in and care at risk.

Take action today: https://buff.ly/UzYnpwi

Attention UnitedHealthcare Medicare Advantage patients!

Happy Halloween from Dr. Gru(Ronholm) & his Minion crew!!

Have questions about living with lupus? Join the Lupus Foundation of America for their annual FREE "Ask the Rheumatologist" program on Wednesday, November 12th at Healix Infusion Care. This interactive program will allow you the opportunity to hear from our own Dr. Chad Ronholm, and get answers to the questions that matter most to you.

This is a great chance to learn more about treatment options, managing symptoms, and what is new in rheumatology care. Don’t miss this informative session. Register with the link provided.

Please share with friends or family that may have questions, also!

Ask the Rheumatologist Get tickets online for Ask the Rheumatologist here.

BREAKING NEWS: The Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab) for the treatment of adults living with lupus nephritis, supported by positive Phase II and III trial results. Gazyva is the fourth therapy for lupus to receive regulatory approval since 2011. This approval is a major step forward in lupus care.

Read the announcement: https://buff.ly/NIcZhAH